IDEAYA Biosciences Inc
IDYAHealthcare|Biotechnology|USA
$36.99
-0.29 (-0.78%)
Tangible Book
$10.67
Financials
Financial Snapshot
Market Cap
$3.56B
Enterprise Value
$642.6M
Revenue (TTM)
$225.3M
Net Income (TTM)
$-140.1M
Cash & Equivalents
—
Net Cash/Share
$6.58
Free Cash Flow (TTM)
$-87.9M
Operating CF (TTM)
$-85.9M
Debt/Equity
0.03
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$21.5M
Monthly Burn
$7.2M
Est. Runway
—
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $13.2M | $90.0M | $99.0M | $283.6M | $246.8M | $364.8M | $525.1M | $676.3M | $639.4M | $671.2M | |
| Operating Cash Flow | $-12.2M | $-27.6M | $-39.3M | $55.5M | $-55.8M | $-87.2M | $-115.2M | $-247.6M | $-71.1M | $-85.9M | |
| Free Cash Flow | $-14.0M | $-29.3M | $-40.7M | $55.0M | $-58.4M | $-90.6M | $-117.6M | $-251.4M | $-73.5M | $-87.9M | |
| Capital Expenditure | $-1.8M | $-1.7M | $-1.4M | $-493.0K | $-2.6M | $-3.4M | $-2.4M | $-3.9M | $-2.4M | $-2.0M | |
| Financing Cash Flow | $17.5M | $105.4M | $50.6M | $128.8M | $145.5M | $97.2M | $362.7M | $677.6M | $29.8M | $4.8M |
R&D Spending
R&D (TTM)
$339.5M
R&D Intensity
150.7%
R&D Growth YoY
+7.9%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $19.5M | $27.9M | $50.9M | $23.4M | $7.0M | $218.7M | $225.3M | |
| R&D Expense | $12.4M | $31.7M | $34.3M | $39.7M | $58.2M | $89.5M | $129.5M | $294.7M | $314.7M | $339.5M | |
| R&D % of Revenue | — | — | — | 203.2% | 208.1% | 175.8% | 553.8% | 4209.6% | 143.9% | 150.7% | |
| SG&A | $2.1M | $4.7M | $10.0M | $15.2M | $20.1M | $23.9M | $28.3M | $39.3M | $63.3M | $69.2M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $19.5M | $27.9M | $50.9M | $23.4M | $7.0M | $218.7M | $225.3M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $19.5M | $27.9M | $50.9M | $23.4M | $7.0M | $218.7M | $225.3M | |
| R&D | $12.4M | $31.7M | $34.3M | $39.7M | $58.2M | $89.5M | $129.5M | $294.7M | $314.7M | $339.5M | |
| SG&A | $2.1M | $4.7M | $10.0M | $15.2M | $20.1M | $23.9M | $28.3M | $39.3M | $63.3M | $69.2M | |
| Operating Income | $-14.4M | $-36.4M | $-44.3M | $-35.3M | $-50.3M | $-62.5M | $-134.4M | $-327.0M | $-159.3M | $-183.5M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-11.9M | $-34.3M | $-42.0M | $-34.5M | $-49.8M | $-58.7M | $-113.0M | $-274.5M | $-113.7M | $-140.1M | |
| Net Income | $-11.9M | $-34.3M | $-42.0M | $-34.5M | $-49.8M | $-58.7M | $-113.0M | $-274.5M | $-113.7M | $-140.1M | |
| EPS (Diluted) | -0.83 | -2.41 | -3.36 | -1.40 | -1.41 | -1.42 | -1.96 | -3.36 | -1.28 | -1.60 | |
| EBITDA | $-14.0M | $-35.5M | $-43.0M | $-34.0M | $-47.2M | $-59.0M | $-130.4M | $-323.1M | $-154.7M | $-178.9M | |
| Shares Out. (M) | 14.24 | 14.24 | 12.50 | 24.72 | 35.25 | 41.45 | 57.52 | 81.68 | 88.48 | 88.70 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.0M | $20.5M | $34.1M | $72.0M | $92.0M | $68.6M | $157.0M | $84.4M | $112.8M | $157.5M | |
| Marketable Securities | $7.2M | $69.5M | $64.9M | $211.5M | $154.7M | $296.2M | $368.1M | $591.9M | $526.6M | $513.7M | |
| Total Current Assets | $13.6M | $90.7M | $101.7M | $288.6M | $251.0M | $370.5M | $532.6M | $689.7M | $666.7M | $696.1M | |
| Total Assets | $17.5M | $96.5M | $113.0M | $298.3M | $381.3M | $388.0M | $649.3M | $1.12B | $1.11B | $1.03B | |
| Total Current Liabilities | $2.4M | $5.4M | $6.9M | $38.6M | $45.2M | $31.7M | $27.1M | $46.1M | $58.8M | $64.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $33.2M | $145.5M | $12.6M | $100.0M | $79.8M | $38.5M | $28.2M | $64.9M | $86.4M | $93.1M | |
| Stockholders' Equity | $-15.7M | $-48.9M | $100.4M | $198.3M | $301.5M | $349.5M | $621.1M | $1.06B | $1.02B | $937.3M | |
| Retained Earnings | $-16.2M | $-50.5M | $-92.5M | $-127.0M | $-176.7M | $-235.4M | $-348.4M | $-622.8M | $-736.5M | $-835.1M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-12.2M | $-27.6M | $-39.3M | $55.5M | $-55.8M | $-87.2M | $-115.2M | $-247.6M | $-71.1M | $-85.9M | |
| Capital Expenditure | $-1.8M | $-1.7M | $-1.4M | $-493.0K | $-2.6M | $-3.4M | $-2.4M | $-3.9M | $-2.4M | $-2.0M | |
| Free Cash Flow | $-14.0M | $-29.3M | $-40.7M | $55.0M | $-58.4M | $-90.6M | $-117.6M | $-251.4M | $-73.5M | $-87.9M | |
| Investing Cash Flow | $-8.9M | $-63.2M | $2.3M | $-146.2M | $-69.7M | $-33.4M | $-158.5M | $-502.6M | $70.0M | $109.1M | |
| Financing Cash Flow | $17.5M | $105.4M | $50.6M | $128.8M | $145.5M | $97.2M | $362.7M | $677.6M | $29.8M | $4.8M | |
| Issuance of Stock | $0.00 | $0.00 | $50.3M | $127.2M | $143.3M | $95.0M | $309.8M | $654.2M | $24.9M | $-154.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-9.0K | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $136.0K | $950.0K | $2.2M | $3.6M | $8.2M | $11.6M | $18.5M | $34.7M | $46.1M | $50.4M | |
| Net Change in Cash | $-3.7M | $14.6M | $13.6M | $38.0M | $20.0M | $-23.4M | $89.0M | $-72.6M | $28.7M | $28.0M |
Dilution Tracker
Shares outstanding grew 151.6% over 5 years — significant dilution
Shares Outstanding
89M
5-Year Share Growth
+151.6%
Stock Issuance (TTM)
$-154.0K
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 14.24 | 14.24 | 12.50 | 24.72 | 35.25 | 41.45 | 57.52 | 81.68 | 88.48 | 88.70 | |
| YoY Change % | — | 0.0% | -12.2% | 97.8% | 42.6% | 17.6% | 38.8% | 42.0% | 8.3% | 0.2% | |
| Stock Issuance | $0.00 | $0.00 | $50.3M | $127.2M | $143.3M | $95.0M | $309.8M | $654.2M | $24.9M | $-154.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-9.0K | |
| Stock Based Comp. | $136.0K | $950.0K | $2.2M | $3.6M | $8.2M | $11.6M | $18.5M | $34.7M | $46.1M | $50.4M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | -180.9% | -179.9% | -122.7% | -574.9% | -4671.1% | -72.8% | -81.4% | |
| Net Margin % | 0.0% | 0.0% | 0.0% | -176.6% | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% | -62.2% | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | -173.8% | -169.1% | -115.8% | -557.7% | -4616.3% | -70.7% | -79.4% | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 281.3% | -209.1% | -177.9% | -502.9% | -3592.0% | -33.6% | -39.0% | |
| ROE % | 0.0% | 0.0% | -163.2% | -23.1% | -19.9% | -18.0% | -23.3% | -32.7% | -10.9% | -13.9% | |
| ROA % | -67.9% | -60.2% | -40.1% | -16.8% | -14.6% | -15.2% | -21.8% | -31.0% | -10.2% | -12.8% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.41
P/S14.71
Historical10.41 / 22.21 / 521.33
Industry Med.9.51
P/B3.47
Historical1.22 / 2.60 / 4.94
Industry Med.2.93
EV/EBITDA-16.32
Historical-21.72 / -9.15 / -1.47
Industry Med.13.14
EV/Revenue12.96
Historical3.20 / 15.10 / 457.61
Industry Med.8.71
P/FCF—
Historical7.52 / 11.55 / 14.29
Industry Med.27.54
Intrinsic Value Models
Tangible Book
$10.67
Net Current Assets
$6.860
Net-Net Working Capital
$6.58
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | 17.72 | 29.81 | 14.78 | 87.42 | 298.84 | 13.98 | 14.71 | |
| PB Ratio | 0.00 | 0.00 | 1.52 | 2.09 | 3.02 | 2.51 | 3.73 | 2.10 | 2.97 | 3.47 | |
| EV/EBITDA | 0.00 | 0.00 | -1.40 | -4.02 | -14.17 | -8.72 | -13.74 | -4.85 | -15.66 | -16.32 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 6.99 | 23.96 | 10.10 | 76.62 | 223.71 | 11.08 | 12.96 |
Analyst Estimates & Quality
Altman Z-Score
22.33
Safe
Piotroski F-Score
3
Weak
Beneish M-Score
25.09
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $32.5M | $121.3M | $220.0M |
| Net Income | $-386.6M | $-372.0M | $-311.6M |
| EPS | -4.29 | -3.73 | -3.34 |
| Book Value per Share | 7.60 | 7.38 | 4.50 |
| Operating Cash Flow per Share | -4.08 | -3.84 | -3.22 |
| Operating CF | $-361.45M | $-340.61M | $-285.17M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Research and development for oncology-focused precision medicine | $218.7M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $218.7M |